Abstract
The aim of this study was to synthesize and evaluate the biological activity of pyrazole derivatives, in particular, to perform a “greener” one-pot synthesis using a solvent-free method as an alternative strategy for synthesizing hydrazono/diazenyl-pyridine-pyrazole hybrid molecules with potential anticancer activity. Effective treatment for all types of cancers is still a long way in the future due to the severe adverse drug reactions and drug resistance associated with current drugs. Therefore, there is a pressing need to develop safer and more effective anticancer agents. In this context, some hybrid analogues containing the bioactive pharmacophores viz. pyrazole, pyridine, and diazo scaffolds were synthesized by one-pot method. Herein, we describe the expedient synthesis of pyrazoles by a onepot three-component condensation of ethyl acetoacetate/acetylacetone, isoniazid, and arenediazonium salts under solvent-free conditions, and the evaluation of their cytotoxicity using a sulforhodamine B assay on three cancer cell lines. Molecular docking studies employing tyrosine kinase were also carried out to evaluate the binding mode of the pyrazole derivatives under study. 1-(4-Pyridinylcarbonyl)-3- methyl-4-(2-arylhydrazono)-2-pyrazolin-5-ones and [4-(2-aryldiazenyl)-3,5-dimethyl-1H-pyrazol-1- yl]-4-pyridinylmethanones, previously described, were prepared using an improved procedure. Among these ten products, 1-isonicotinoyl-3-methyl-4-[2-(4-nitrophenyl)hydrazono]-2-pyrazolin-5-one (1f) displayed promising anticancer activity against the MCF-7, HepG2 and HCT-116 cell lines, with an IC50 value in the range of 0.2-3.4 μM. In summary, our findings suggest that pyrazoles containing hydrazono/ diazenyl and pyridine pharmacophores constitute promising scaffolds for the development of new anticancer agents.
Keywords: Anticancer agents, cytotoxic agents, one-pot synthesis, pyrazole, pyridine, sulforhodamine B assay.
Graphical Abstract
[http://dx.doi.org/10.3961/jpmph.2013.46.4.165] [PMID: 23946874]
(b)Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[http://dx.doi.org/10.1186/s40169-018-0185-6] [PMID: 29541939]
[http://dx.doi.org/10.1016/j.cbpa.2010.02.018] [PMID: 20303320]
[http://dx.doi.org/10.1248/bpb.34.1774] [PMID: 22130229]
(b)Ou, S-H.I. Drug Des. Devel. Ther., 2011, 5, 471-485.
[http://dx.doi.org/10.2147/DDDT.S19045] [PMID: 22162641]
(c)Strocchi, E.; Fornari, F.; Minguzzi, M.; Gramantieri, L.; Milazzo, M.; Rebuttini, V.; Breviglieri, S.; Camaggi, C.M.; Locatelli, E.; Bolondi, L.; Comes-Franchini, M. Eur. J. Med. Chem., 2012, 48, 391-401.
[http://dx.doi.org/10.1016/j.ejmech.2011.12.031] [PMID: 22227043]
[http://dx.doi.org/10.1016/S0960-894X(00)80254-1]
[http://dx.doi.org/10.2174/187152008783961941] [PMID: 18393788]
(b)Arafath, M.A.; Adam, F.; Al-Suede, F.S.R.; Razali, M.R.; Ahamed, M.B.K.; Majid, A.M.S.A.; Hassan, M.Z.; Osman, H.; Abubakar, S. J. Mol. Struct., 2017, 1149, 216-228.
[http://dx.doi.org/10.1016/j.molstruc.2017.07.092]
[http://dx.doi.org/10.5155/eurjchem.2.2.238-242.206]
[http://dx.doi.org/10.1080/15533179308016700]
[http://dx.doi.org/10.3109/14756366.2011.607446] [PMID: 21883038]
[http://dx.doi.org/10.1093/jnci/82.13.1107] [PMID: 2359136]
[http://dx.doi.org/10.1515/revic-2018-0007]
[http://dx.doi.org/10.1016/S0040-4020(01)97246-1]
[http://dx.doi.org/10.1074/jbc.M207135200] [PMID: 12196540]